TrialBMC medicine2023

Anlotinib as a third-line or further treatment for recurrent or metastatic nasopharyngeal carcinoma: a single-arm, phase 2 clinical trial.

Yu Fang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.